Ask the expert: How will Brexit affect Parkinson’s drugs and research?
Author: Simge Eva DoganPublished: 30 January 2020
Prep: Cook: Serves:
The UK is due to
formally leave the European Union this week. In the second in our series where
we ask experts about the biggest issues facing the Parkinson’s community, Dr
Kieran Breen of the European Medicines Agency Committee for Advanced Therapies gives
his views on the likely impact of Brexit – from the availability of Parkinson’s
medication to international research collaboration
First of all, could you explain to our readers how
Brexit might affect people with Parkinson’s? Will there be an impact on the
supply of medications?
It’s very difficult to look into the future, but yes, the
availability of the therapies and drugs for people with Parkinson’s may be
impacted. We don’t know how things are going to develop in the transition period
over the next 11 months, but it could be that when drugs are coming through
customs they are delayed at the point of entry to the country.
I would imagine that because pharmaceuticals are so
important to the lives of people in the UK with Parkinson’s and every other
condition, that the manufacturing standards are going to stay the same here as
with the rest of Europe.
What might happen to Parkinson’s drugs manufacturing in
At the moment, within Europe, the quality of drug
manufacture is the same throughout the 28 countries. The manufacturing is
usually assessed at a local level, so in the UK that would be the Medicines and
Healthcare products Regulatory Agency (MHRA), which is responsible for drug
If the MHRA assess and approve a drug at a manufacturing
site, it can go anywhere to 28 countries. However, come Brexit, what will
happen is that will no longer be the case. Any drugs manufactured in the UK
cannot automatically be sent to the 27 countries and vice versa.
Theoretically what would happen in the case of a hard Brexit is somebody from the UK will have to go to wherever the drug is manufactured and assess the quality of the manufacturing process. It’s unlikely that this will happen, but it’s a possibility.
Will Brexit impact Parkinson’s drug trials?
Once the UK is no longer in the EU, it will be less likely
that drug trials will be carried out in the UK, because the agreed standards may
be different. Also, if companies want to license a new drug, will they submit
the marketing authorisation application to the European Medicines Agency (EMA),
which is around 600 million people, or submit it to the UK, which is 60 million
people? Well, it’s a no brainer that companies are more likely to submit to the
EU funding supports a substantial amount of medical research in the UK. What effect do you think that Brexit will have for the future of Parkinson’s research and innovation in the UK?
There are two sources of funding
in the UK for Parkinson’s research – charity funding and government funding.
With government funding you can never tell what’s going to come up by the next
budget, but UK charities will continue to fund research. I don’t think Brexit
will have a significant impact on that.
The main area where there is
going to be a problem is European research funding. The European Commission
I don’t know off-hand how much of that goes to Parkinson’s.
Once Brexit happens, UK
researchers will no longer have access to EU funding, so it will choke off the
finance but it will also provide a barrier to international interaction. Interacting
with other people and exchanging ideas is a really important part of research. International
collaboration facilitates the development of new therapies, treatments,
diagnostic models and really increases the understanding of Parkinson’s.
What’s your advice for people in the Parkinson’s
community wondering how best to prepare for these changes?
With Brexit, who knows what’s going to happen? Patient organisations and patients’ collaborators need to
keep a very close eye on what’s happening from a Brexit perspective and make
sure they are talking to the right people so that their voices are heard.
Patients and healthcare professionals need to work with organisations to make sure that the agenda is moved forward – and make sure that MPs are aware of the implications of Brexit from a patient’s perspective. It’s really important that the topic of drug availability remains on the agenda.
Need to know: Dr Kieran Breen is a UK-based pharmacologist. He worked at Parkinson’s UK for nine years as Director of Research & Innovation. He was nominated by the EPDA to join the European Medicines Agency Committee for Advanced Therapies in 2013 – a group which deals with the next generation of therapies.
At a glance: Parkinson’s and Brexit
Brexit may affect the availability of Parkinson’s therapies and drugs in the UK.
It will be less likely that drug trials are carried out in the UK after Brexit.
After Brexit, UK researchers will no longer have access to EU funding which may affect both the financing of new studies and international collaboration.
Parkinson’s organisations need to make sure that patient voices are heard during the transition and lobby the government to ensure that drug availability remains on the agenda.
Can tremor predict the effect of Parkinson’s disease medication?
Researchers from the Netherlands have found a link between tremor symptoms and how dopaminergic medication impacts learning abilities in Parkinson’s disease. Many people with Parkinson’s become sensitive to learning through rewards due to a decrease in dopamine in the brain. As part of a new study – published in the scientific journal Brain –researchers assessed 43 tremor-dominant and 20 non-tremor dominant people with Parkinson’s while they were on and off dopaminergic medication. The results showed that in people with Parkinson’s who do not experience tremor, dopaminergic medication improves the ability to learn from rewards – and in those with tremor, the medication has no impact on reward learning. Rick Helmich, co-author of the study and a neurologist at Radboud University Medical Centre, the Netherlands, said: “Whether someone experiences tremor or not might therefore potentially have a significant predictive value regarding the effectiveness of medication in the cognitive domain. However, more…
Could a ‘Mediterranean diet’ lower the risk of Parkinson’s for women?
A study by scientists in Sweden has suggested that women who eat a ‘Mediterranean diet’ at middle age could have a lower risk of Parkinson’s later in life. The report, published in the Movement Disorders journal, used dietary information from more than 47,000 women aged 29 to 49, recorded between the early 1990s and 2012. They looked at how closely the women adhered to a Mediterranean dietary pattern (MDP), which is high in foods such as vegetables, fruits, nuts, unsaturated fats and legumes. They then compared the information with data from the Swedish National Patient Register to find out whether participants had been diagnosed with Parkinson’s. The researchers found that those with a high adherence to the diet had a 46% lower risk of being diagnosed with the condition compared to those with a low adherence, concluding that “higher adherence to a Mediterranean diet at middle age was associated with…
3 weeks ago
Pesticide that increases Parkinson’s risk by 150% reapproved in the US
The US Environmental Protection Agency (EPA) has allowed the continued use of paraquat, a pesticide that increases the risk of Parkinson’s disease by 150%. The pesticide – which has already been banned in 32 countries – was reapproved by the EPA in October as part of a review of the safety of all herbicides and pesticides in the US, a process which takes place every 15 years. Many studies have shown that as well as increased risk of Parkinson’s disease, exposure to the pesticide is associated with other health issues and risk of death. Exposure to paraquat endangers both the farmers who use the pesticide, as well as the families who can be exposed to it through the air or transfers onto clothing or other materials. In response to the reapproval, the Michael J Fox Foundation is calling on the Parkinson’s community to ask senators and representatives to support a…